Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
نویسندگان
چکیده
منابع مشابه
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody
The Mammary Prevention 3 (MAP.3) placebo-controlled randomized trial in 4,560 high-risk postmenopausal women showed a 65% reduction in invasive breast cancer with the use of exemestane at 35 months of median follow-up. Few differences in adverse events were observed between the arms, suggesting a promising risk:benefi t balance with exemestane for use in chemoprevention. Yet, the MAP.3 design a...
متن کاملPathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
Objectives. To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting. Methods. Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical cystectomy between 2003 and 2011. Outcomes of interest included those with complete response (pT0) ...
متن کاملVillous Adenoma Coexisting with Non-Muscle Invasive Urothelial Carcinoma of the Bladder, Case Report
A 72-year old patient was admitted to hospital with the complaint of non-coagulated hematuria and pain. There was no remarkable finding in physical examination. Cystoscopic examination revealed two papillary tumors in the urinary bladder. Larger one measuring 25 mm was on the dome of bladder and the other was 16 mm mass in the left wall of urinary bladder, with enhancement. Cold punch biopsy wa...
متن کاملThe ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
INTRODUCTION Randomized controlled trials of platinum-based neoadjuvant chemotherapy (NAC) for bladder cancer have shown that patients who achieve a pathologic response to NAC exhibit 5 y survival rates of approximately 80-90% while NAC resistant (NR) cases exhibit 5 y survival rates of approximately 30-40%. These findings highlight the need to predict who will benefit from conventional NAC and...
متن کاملRole of FGFR3 in Urothelial Carcinoma
Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods: A retrospective study was undertaken on paraffin blocks o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Discovery
سال: 2014
ISSN: 2159-8274,2159-8290
DOI: 10.1158/2159-8290.cd-14-0623